Not producing, distributing Covishield since December 2021: Serum Institute

AstraZeneca Covid vaccine row: As of April 30, 2024, over 1.7 billion doses of the Covishield vaccine has been administered in India

Covishield, Vaccine, AstraZeneca
Photo: Wikimedia Commons
Rimjhim Singh New Delhi
2 min read Last Updated : May 09 2024 | 12:33 PM IST
The Serum Institute of India (SII), manufacturer of the AstraZeneca Covid vaccine branded as Covishield, announced that it has stopped the production and distribution of vaccine doses since December 2021.

After AstraZeneca withdrew its Covid vaccine, the SII said it acknowledges and fully understands the ongoing concerns regarding the vaccine from the UK pharmaceutical company, according to a report in Moneycontrol.

A spokesperson from SII said the company is committed to transparency and safety, emphasising that all necessary measures had been undertaken to disclose the vaccine's rare side effects.

On May 7, the UK firm had announced its decision to globally withdraw its Covid vaccine, citing the availability of numerous newer vaccine options as the reason. Furthermore, AstraZeneca intends to retract marketing authorisations for its vaccine, Vaxzevria, across Europe, citing decreased demand and the discontinuation of production and supply.

On April 29, AstraZeneca, a leading manufacturer of Covid-19 vaccines distributed to millions globally, particularly in India, stated in the UK court documents for the first time that its Covid-19 vaccine, marketed worldwide as Covishield and Vaxzevria, among other names, may be associated with a rare and potentially fatal side effect, thrombosis with thrombocytopenia syndrome (TTS).

In January 2021, Pune-based SII entered into a strategic collaboration with AstraZeneca and the University of Oxford to produce the Covishield vaccine for India and various low- and middle-income nations. As of April 30, 2024, over 1.7 billion doses of the Covishield vaccines have been administered in India.

Side effects of AstraZeneca vaccine

The World Health Organisation (WHO) outlines the potential side-effects of the AstraZeneca vaccine, which generally consist of mild to moderate symptoms that are typically short-lived and resolve on their own. Typical side-effects reported post-AstraZeneca vaccination include discomfort at the injection site, fatigue, fever, headache, nausea, muscle or joint pain, swelling, redness at the injection site, dizziness, drowsiness, and sweating.

Following the controversy, various countries banned the vaccine, including Denmark, the Netherlands, Norway, Iceland, Congo, and Bulgaria. Certain European nations such as Germany, France, Italy, and Spain stopped the administration of AstraZeneca's Covid-19 vaccine in 2021 due to instances of blood clotting among vaccinated individuals.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusAstraZenecahealthhealthcareCoronavirus VaccineSerum Institute of IndiaSerum InstituteBS Web ReportsVaccine

First Published: May 09 2024 | 12:33 PM IST

Next Story